

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-10 (Canceled).

Claim 11 (Previously Presented): A composition for nasal absorption comprising a carrier,

wherein the carrier is calcium carbonate, calcium phosphate, or a combination thereof,

wherein the carrier has an average particle size of 20 to 100 μm ,
and

an effective dose of an opioid analgesic,

wherein the effective dose of the opioid analgesic is uniformly distributed and attached to the carrier, and

wherein the opioid analgesic is at least one analgesic selected from the group consisting of morphine hydrochloride, morphine sulfate, morphine hydrochloride/atropine sulfate preparation, fentanyl, fentanyl citrate, droperidol/fentanyl citrate preparation, and buprenorphine hydrochloride.

Claim 12 (Previously Presented): The composition of claim 11, wherein the carrier is calcium carbonate.

Claim 13 (Previously Presented): The composition of claim 11, wherein the carrier is calcium phosphate.

Claim 14 (Previously Presented): The composition of claim 11, wherein the carrier is a combination of calcium carbonate and calcium phosphate.

Claim 15 (Previously Presented): The composition of claim 11, wherein the content of the opioid analgesic is from 0.01 to 50% by weight, and wherein the content of the carrier is from 50 to 99.99% by weight.

Claim 16 (Previously Presented): A method of treating pain in a patient in need thereof, comprising intranasally administering the composition of claim 11 to the patient in need thereof, in an amount sufficient to treat the pain.

Claim 17 (Previously Presented): The method of claim 16, wherein the pain is postsurgery pain.

Claim 18 (Previously Presented): The method of claim 17, wherein the pain is cancer pain.

Claim 19 (Previously Presented): The method of claim 18, wherein the cancer of the cancer pain is terminal cancer.

Claim 20 (Previously Presented): The method of claim 18, wherein the cancer of the cancer pain is cancer of the digestive system.

Claims 21-22 (Canceled).